Evaluation of Mild Transaminitis in a 68-Year-Old Male
Order an abdominal ultrasound and obtain a comprehensive metabolic workup including hepatitis B surface antigen, hepatitis C antibody, fasting glucose/lipid panel, iron studies (ferritin, transferrin saturation, total iron-binding capacity), and review all medications including over-the-counter drugs and supplements 1, 2.
Understanding the Pattern
This patient has a hepatocellular pattern of injury (ALT 128 U/L, AST 73 U/L) with an AST:ALT ratio <1, which is classified as mild elevation (<5 times the upper limit of normal, assuming ULN ~40 U/L) 1. The ALT predominance suggests metabolic liver disease rather than alcohol-related injury, which typically shows AST:ALT ratio >2 1.
Most Likely Diagnoses
The two most common causes accounting for the majority of mild transaminitis cases are:
- Metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Prevalence 20-30% in general population, increasing to 70% with obesity and 90% with diabetes 1
- Alcohol-induced liver disease: Second most common cause 1, 2
Uncommon but important causes include drug-induced liver injury, chronic hepatitis B and C, and hereditary hemochromatosis 1, 2, 3.
Initial Diagnostic Workup
Laboratory Testing (First-Line)
Essential serologic tests 1, 2, 3, 4:
- Hepatitis B surface antigen (HBsAg)
- Hepatitis C antibody
- Iron studies: serum iron, total iron-binding capacity, ferritin
- Fasting glucose and lipid panel (assess for metabolic syndrome)
- Complete blood count with platelets
- Serum albumin (assess synthetic function)
Imaging
Abdominal ultrasound is the first-line imaging modality for mild transaminase elevation 1. Ultrasound can:
- Detect hepatic steatosis with 84.8% sensitivity and 93.6% specificity when fat content >30% 1
- Identify biliary obstruction or masses
- Assess for cirrhosis features
Important caveat: Ultrasound sensitivity drops to 53-65% for mild steatosis and is less reliable with concurrent inflammation or fibrosis 1.
Medication Review
Critical step: Obtain detailed history of all medications started within the past 12 months, including 5, 2:
- Prescription medications
- Over-the-counter drugs
- Herbal supplements
- Dietary supplements
Consider stopping or substituting any potentially hepatotoxic agents 5.
Risk Stratification for Fibrosis
If MASLD is suspected based on initial workup, calculate FIB-4 Index Score or NAFLD Fibrosis Score to identify patients at risk for significant fibrosis who may benefit from hepatology referral 2, 3.
When to Pursue Additional Testing
If initial workup is unrevealing, consider second-tier testing for uncommon causes 2, 3, 4:
- Alpha-1 antitrypsin level and phenotype
- Autoimmune hepatitis panel (ANA, anti-smooth muscle antibody, serum IgG)
- Ceruloplasmin and 24-hour urine copper (Wilson disease, if age <40)
- Celiac serology (tissue transglutaminase antibody)
- Thyroid function tests
- Creatine kinase (if AST disproportionately elevated, consider muscle source)
Management Approach
If MASLD/NAFLD Suspected
- Lifestyle modification trial: Weight loss, dietary changes, increased physical activity 2, 3
- Counsel on alcohol cessation or moderation 2
- Optimize metabolic risk factors (diabetes, hyperlipidemia, hypertension)
Monitoring Strategy
- Repeat liver enzymes in 3 months if initial workup unrevealing and patient asymptomatic 6
- If elevation persists after lifestyle modification trial, proceed with hepatic ultrasonography (if not already done) and testing for uncommon causes 3
Red Flags Requiring Expedited Evaluation
The following warrant more urgent assessment 7, 8:
- Symptoms of liver disease (jaundice, ascites, encephalopathy)
- Evidence of synthetic dysfunction (low albumin, elevated INR)
- Bilirubin elevation
- Thrombocytopenia suggesting portal hypertension
- Transaminases >5× ULN
Key Clinical Pitfall
Do not assume the "normal" upper limit is truly normal. Current reference ranges may be too high due to inclusion of patients with occult NAFLD. For chronic hepatitis B, treatment guidelines use ALT >30 U/L for males and >19 U/L for females as significant 8. This patient's ALT of 128 U/L is clearly abnormal and warrants full evaluation regardless of laboratory reference ranges.
The magnitude of transaminase elevation does not correlate with prognosis—diagnosis and context matter more 8. Patients with hepatitis C can have normal ALT yet progress to cirrhosis, while acute hepatitis A with ALT >1000 U/L typically resolves without sequelae 8.